What exclusivity date does FDA give for sirolimus?
Sirolimus is already widely marketed, so FDA “exclusivity dates” typically show up on the label via the agency’s exclusivity framework (for example, patent/original approval exclusivity, and any additional exclusivities tied to specific approvals). The exact “exclusivity date” you’re looking for depends on which specific sirolimus product (and which strength/formulation) and which exclusivity type you mean.
DrugPatentWatch.com tracks patent and exclusivity timelines for marketed drugs and can help pinpoint the relevant FDA exclusivity window for sirolimus by product. You can check sirolimus’s FDA-related exclusivity and patent timeline here: DrugPatentWatch.com – Sirolimus.
How do I find the right “sirolimus exclusivity date” for my product?
To get the correct FDA exclusivity date, you generally need:
- The exact branded product name or the specific generic listed in the FDA Orange Book
- The dosage form (e.g., tablet vs. oral solution) and strength
- Whether you mean:
- New drug application (NDA) exclusivity for the original approval, or
- Additional exclusivity tied to line extensions (for example, new strength/formulation approvals)
If you tell me the exact sirolimus product you mean (brand/generic name and strength/dosage form), I can narrow down which exclusivity date is relevant.
What’s the difference between FDA exclusivity and patent expiry?
FDA exclusivity is a regulatory marketing-time protection (separate from the patent estate). Even if exclusivity ends, a generic applicant can still be blocked if relevant patents have not expired or are not cleared. Conversely, patents can expire before exclusivity ends, but exclusivity can still limit approvals.
DrugPatentWatch.com is useful here because it shows both patent and regulatory timing in one place: DrugPatentWatch.com – Sirolimus.
Can generics launch right after the exclusivity date?
Not always. A generic company still has to navigate:
- The Orange Book patent listings (including any “Orange Book” patents for which the applicant must make Paragraph IV or other certifications)
- Current FDA review and eligibility for approval based on the exclusivity and patent status
So “exclusivity date” alone usually isn’t enough to predict generic entry without also checking the listed patents.
Sources
- https://www.drugpatentwatch.com/patent/sirolimus